Sandoz began its journey as an independent company.Pharmaceutical laboratories specializing in generic drugs (generics or biosimilars) have announced investments Investment of €50 million until 2025 in the expansion of the Palafoss plant (Barcelona). The business is part of a project to strengthen and modernize its European antibiotic production network.
The company ceased to be part of the Novartis structure on October 4 and has since Independent Company VI of the Swiss Exchange. To this end, the company announced that it is strengthening its global network of centers, adding approximately 150 new members to the company’s team. Sandoz has seven such centers in Madrid.
Joaquín Rodrigo, President of Sandoz Spain and General Manager of the Iberia Division, assures: “Our new brand reflects our long-term commitment to healthcare innovation and our commitment to Addressing global healthcare challenges”, in the words of the manager.
Sandoz was spun off from Novartis on October 4 after being listed on the SIX Swiss Stock Exchange.
Specifically, the Sandoz Iberia team plans to offer vademecum, which contains more than 200 molecules, to professionals and patients, with more than 600 benefits, including One hundred biological patents and eight biosimilars Covers major therapeutic areas. Second, the company plans to bet that “through horizontal collaboration with health institutions, Provide information attention and continuous training to its professionals“.
Sandoz works with generic or biosimilar medicines to promote better health for patients. Its product portfolio totals more than 1,500 medicines that treat conditions ranging from the common cold to cancer. Headquartered in Basel (Switzerland), Its origins date back to 1886.
After the spin-off of Sandoz, Novartis pledged to focus its entire strategy on the management of innovative medicines. Additionally, the company reiterated its forecast for fiscal 2023, ensuring that sales and operating income are expected to grow by around 10%. Between 10% and 15%.